In summary, our findings reveal that downregulation of CRL4 is responsible for downregulation of BIRC3 in ovarian cancer and that CRL4 plays an important role in apoptosis and chemoresistance in ovarian cancer by targeting BIRC3. Here, IL17RB is linked to ovarian carcinoma.